Navigation Links
Rib-X Pharmaceuticals Novel Antibiotic Delafloxacin Named One of R&D Directions 100 Great Investigational Drugs of 2009
Date:4/2/2009

NEW HAVEN, Conn., April 2 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ("Rib-X" or the "Company"), a development-stage company focused on the discovery and development of novel antibiotics for the treatment of antibiotic-resistant infections, today announced that its lead compound, delafloxacin, has been selected by R&D Directions editors for the 8th annual report on "100 Great Investigational Drugs," published in the March 2009 issue.

R&D Directions is a leading pharmaceutical industry magazine. Compounds selected by editors for the report, including delafloxacin, demonstrated "particular promise in a... growing therapeutic area of unmet medical need... and target disease pathways using a distinctly innovative mechanism of action."(1)

"We are honored to have our lead compound, delafloxacin, recognized by the editors of R&D Directions as one of the top 100 investigational drugs of 2009," said Susan Froshauer, PhD, President and CEO of Rib-X Pharmaceuticals. "The broad spectrum activity demonstrated by delafloxacin against a wide range of highly-resistant bacteria may offer the medical community a much needed treatment alternative for a variety of serious hospital treated infections, including complicated skin, hospital acquired pneumonia, endocarditis and others. We are proud of the work we have done at Rib-X to further the development of this compound."

A copy of the R&D Directions 100 Great Investigational Drugs of 2009 report can be viewed at http://www.rddirections.com/magazines/randd/.

About Delafloxacin

Delafloxacin, a novel, broad spectrum, next-generation fluoroquinolone, has demonstrated better activity than other quinolones against Gram-positive bacteria, including isolates of MRSA that are re
'/>"/>

SOURCE Rib-X Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Rib-X Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Study of Delafloxacin
2. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
3. Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
4. Rib-X Pharmaceuticals Initiates Phase 2 Trial for RX-3341 In Complicated Skin and Skin Structure Infections
5. Rib-X Pharmaceuticals Renews Collaborative Agreement with the Medical Research Council
6. Rib-X Pharmaceuticals to Present at 10th Annual Superbugs & Superdrugs Conference
7. Arena Pharmaceuticals to Host Conference Call and Webcast on Monday, March 30, 2009 to Discuss Lorcaserin Pivotal Phase 3 Obesity Trial Results
8. Oramed Pharmaceuticals to Present Oral Insulin Phase 2A Trial Results at the Upcoming Annual Meeting of the ADA (June 5-9, New Orleans, LA)
9. XTL Biopharmaceuticals Announces the Acquisition of the Use Patent on Recombinant Erythropoietin (rHuEPO) for the Treatment of Multiple Myeloma
10. Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update
11. Avineuro Pharmaceuticals, Inc. Announces Beginning of Phase I Clinical Studies of AVN-211, Potent Small Molecule for Treatment of Schizophrenia.

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...RNewswire-FirstCall/ -- Virtual Health Technologie... that the previously confirmed Letter of Intent to...gement Technologies, Inc (WNDM) is subject to fina...ders of VHGI. ,, Shareholder Assurances ,...royalty stream and cash realized from the transact...
(Date:11/6/2009)....C., Nov. 6 Chimerix, Inc., a biop...ntiviral therapeutics to address life-threatening ...the company,s lead antiviral compound, CMX001, to ... Health Security Initiative (GHSI). CMX001 is a b...the treatment of smallpox, as well as other seriou...
(Date:11/6/2009)...wire/ -- California American Water has designated ... Drain" week for its San Diego County service area...c and private agencies alike toward the common mis...ource water supplies. ,, California American Wa... drop off expired or unwanted pharmaceuticals free...
Breaking Medicine Technology:OTCBB-VHGI Updates Shareholders on Status of Healthcare Asset Sale and Treasure Gulch Gold Mine Development Strategy 2OTCBB-VHGI Updates Shareholders on Status of Healthcare Asset Sale and Treasure Gulch Gold Mine Development Strategy 3OTCBB-VHGI Updates Shareholders on Status of Healthcare Asset Sale and Treasure Gulch Gold Mine Development Strategy 4Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox 2Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox 3California American Water Celebrates 'No Drugs Down the Drain' Week in San Diego 2New oral agents may prevent injury after radiation exposure 51333 1New oral agents may prevent injury after radiation exposure 51333 2University of Hawaii at Manoa professor published in science journal 9207 1A complete view of complexity in science and society in a new authoritative reference work 9205 1A complete view of complexity in science and society in a new authoritative reference work 9205 2
...007 - AVANIR,Pharmaceuticals (NASDAQ:AVNR) today a...d improvements in patient-centered outcomes in,pat...ain treated,with the investigational drug Zenvia(T...d in two scientific posters at the,Second Internat...Berlin, Germany on June 7 to 10, 2007., Both poste...
...Results of a Phase 2a,clinical trial evaluating th...t hospital acquired gram-negative bacterial,pneumo...iety (ATS),International Conference, May 18 - 23, ... Niederman, MD, Chairman, Department of, ... of, Medicine; Vice Chairman, Department...
Other Medicine Technology:AVANIR Pharmaceuticals to Present Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at Second International Congress on,Neuropathic Pain 2AVANIR Pharmaceuticals to Present Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at Second International Congress on,Neuropathic Pain 3AVANIR Pharmaceuticals to Present Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at Second International Congress on,Neuropathic Pain 4Clinical Trial Data (Phase 2a) Regarding Inhaled Amikacin Will Be,Presented at American Thoracic Society International Conference 2Clinical Trial Data (Phase 2a) Regarding Inhaled Amikacin Will Be,Presented at American Thoracic Society International Conference 3
(Date:11/7/2009)...USNewswire/ -- With the final House vote on health...ding the entire bill hostage to further their anti...go far beyond the status quo restrictions on abort...ill. In an outrageous amendment, which is expecte...ice Democrats are demanding explicit and unequivoc...
(Date:11/7/2009)...USNewswire/ -- Speaker Nancy Pelosi and Democratic...following a Democratic Whip meeting with President...peaker,s opening remarks: ,, "Thank you very m...s to receive the President of the United States on...vote and making progress for the American people. ...
(Date:11/7/2009)...h will rebel, expert says , , SATURDAY, No...behave badly if their parents expect them to, a ne...y are simply being realistic might actually contri...nan, a psychology professor at Wake Forest Univers...ty news release. "Negative expectations on the par...
(Date:11/7/2009)...nt economic climate, many Americans are monitoring...oney on what that they consider to be absolutely e...m believes that it’s very important for over...t to improve their health, and he is trying to mak...is tough economy by offering reasonable prices and...
(Date:11/6/2009)..., Nov. 6 /PRNewswire-FirstCall/ - Cardiome Pharma ...that it will report financial results for the thir...of Monday, November 9, 2009. Cardiome will hold a ...(6:00am Pacific) on that day to discuss the result...16-695-7806 or 888-789-9572 and reference conferen...
Breaking Medicine News(10 mins):Health News:Pelosi Remarks Following House Democrats' Meeting with President Obama 2Health News:Bad-Behaving Teens May Be Living Up to Expectations 2Health News:Dallas Bariatric Surgeon Offers Multiple Options for Patients Considering Weight Loss Surgery in a Rough Economy 2Health News:Dallas Bariatric Surgeon Offers Multiple Options for Patients Considering Weight Loss Surgery in a Rough Economy 3Health News:Cardiome to Release Third Quarter Results 2Health News:Cardiome to Release Third Quarter Results 3
... VALLEY, Calif., Feb. 12 Kovarus, Inc., a premier...xpert custom cycling shop in,Mill Valley, today jo...cated,to the promotion of cycling while also incre... , The Studio Velo/Kovarus Cycling Club (SVK-C...
...RIA, Calif., Feb. 12 The Centers for Disease Cont...eart disease is America,s leading cause of death. ...a new heart-related coronary attack, and about 470...de information about heart disease. The Internati...
...E, Md., Feb. 12 Neuralstem, Inc. (NYSE Alternext ... Senator (D-Tennessee) and former Ambassador to th...lstem Advisory Board and will serve as senior advi...om Tennessee in 1976 where he served for eighteen ...
....J., Feb. 12 DOR BioPharma, Inc. (OTC Bulletin Bo...at it has signed a potential $30 million partnerin... (Sigma - Tau) for the development and commerciali...upfront investment in DOR, inclusive of the $1.5 m...
... Where One Chicago Family Turned W... Chicago, IL (PRWEB) Febru... She is a grandmother of two. She is the primary ...ised her granddaughter, too. , , , , ,But what ha...
...la to Receive $75 Million Upfront Cash Payment, $5...yalties on Future Sales -- , , SOUTH SAN FRANCISC... a privately-held biopharmaceutical company develo...wide license agreement with Novartis to develop an...
Other Medicine News:Health News:Biking for Fun, Sport, and Brain Tumor Awareness 2Health News:Biking for Fun, Sport, and Brain Tumor Awareness 3Health News:The ISSA Offers 8 Tips for American Heart Month 2Health News:Senator James Sasser, Former Ambassador to China, Joins Neuralstem Advisory Board 2Health News:Senator James Sasser, Former Ambassador to China, Joins Neuralstem Advisory Board 3Health News:DOR BioPharma Announces Potential $30 Million North American Partnership Agreement with Sigma-Tau Pharmaceuticals for orBec(R) in the Treatment of Graft-versus-Host Disease 2Health News:DOR BioPharma Announces Potential $30 Million North American Partnership Agreement with Sigma-Tau Pharmaceuticals for orBec(R) in the Treatment of Graft-versus-Host Disease 3Health News:DOR BioPharma Announces Potential $30 Million North American Partnership Agreement with Sigma-Tau Pharmaceuticals for orBec(R) in the Treatment of Graft-versus-Host Disease 4Health News:DOR BioPharma Announces Potential $30 Million North American Partnership Agreement with Sigma-Tau Pharmaceuticals for orBec(R) in the Treatment of Graft-versus-Host Disease 5Health News:DOR BioPharma Announces Potential $30 Million North American Partnership Agreement with Sigma-Tau Pharmaceuticals for orBec(R) in the Treatment of Graft-versus-Host Disease 6Health News:DOR BioPharma Announces Potential $30 Million North American Partnership Agreement with Sigma-Tau Pharmaceuticals for orBec(R) in the Treatment of Graft-versus-Host Disease 7Health News:Taking Care of the Caregiver 2Health News:Taking Care of the Caregiver 3Health News:Portola Pharmaceuticals Enters Worldwide License Agreement for Development and Commercialization of Novel Antiplatelet Drug Elinogrel 2Health News:Portola Pharmaceuticals Enters Worldwide License Agreement for Development and Commercialization of Novel Antiplatelet Drug Elinogrel 3
...eference laboratory and a worldwide leader in inno...ffers an extensive test menu of highly complex and...hology. Owned by the University of Utah, ARUP Labo...tion's university teaching hospitals and children'...
...eference laboratory and a worldwide leader in inno...ffers an extensive test menu of highly complex and...hology. Owned by the University of Utah, ARUP Labo...tion's university teaching hospitals and children'...
...eference laboratory and a worldwide leader in inno...ffers an extensive test menu of highly complex and...hology. Owned by the University of Utah, ARUP Labo...tion's university teaching hospitals and children'...
...eference laboratory and a worldwide leader in inno...ffers an extensive test menu of highly complex and...hology. Owned by the University of Utah, ARUP Labo...tion's university teaching hospitals and children'...
Medicine Products: